Friday, July 18 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, July 18 9:30–11:45am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, July 17 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Friday, July 18 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, July 18 9:30–11:45am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Friday, July 18 12:45–1:45pm
Cardiology in Focus: Breaking Down the Latest Guideline Updates
Friday, July 18 9:30–11:45am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, July 17 12:45–1:45pm
Skin Deep: Tackling Everyday Dermatologic Cases in Primary Care
Friday, July 18 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, July 18 9:30–11:45am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, July 17 3:45–5:15pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, July 17 7:30–8:30am
Thursday, July 17 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Thursday, July 17 10:45–11:45am
Thursday, July 17 3:45–5:15pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, July 17 2:45–3:30pm
Breakthroughs in Psychiatry: Emerging Treatments for Common Disorders
Disclosures
The following financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Relevant relationships will be disclosed at the start of each presentation.
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- Researcher: AbbVie; Speaker: AbbVie, Lilly, Scilex, Lundbeck, Averitas Pharma, Teva, Impel, Kowa Pharmaceuticals, Nevro; Consultant: Collegium, Scilex, Vertex, Xgene Pharma, Tris, PainScripts, Nevro; Other: Lundbeck and Teva; Stock Holder (publicly traded company): Pfizer and Trevana
- Andrew E. Budson, MD
- Advisor: Eli Lilly and AbbVie; Independent Contractor: Vox Neuro and Bristol Meyers Squibb
- Oscar A. de Leon-Casasola, MD
- Consultant: Merck Pharmaceuticals, Vertex Pharmaceuticals.
- Stephanie Faubion, MD, MBA, FACP, NCMP, IF
- Information to come
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Consultant: OptumRx, Premier, Inc.
- Aubrey J. Grant, MD, FACC
- No relevant financial relationships disclosed.
- Stephen N. Henry, DO, MS
- No relevant financial relationships disclosed.
- Pamela Kushner, MD, FAAFP
- Advisor: GlaxoSmithKline, Novo Nordisk, AstraZeneca, Lilly, Abbott, Haleon, Bausch/SALIX, Corcept, Boehringer Ingelheim; Speaker: Novo Nordisk, Lilly, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Abbott, Phathom, Bausch/SALIX, Intuity, Pfizer, and Janssen.
- Avery Lachance, MD, MPH
- Consultant: Guidepoint, J&J, Pfizer; Researcher: Merck, Pfizer; Advisor: TD Cowen
- Bruce D. Nicholson, MD
- No relevant financial relationships disclosed.
- Joynita R. Nicholson, DO, DABOM, FOMA
- No relevant financial relationships disclosed.
- Philip Schoenfeld, MD, MSEd, MSc
- Speaker: Ironwood Pharmaceuticals, Ardelyx Pharmaceuticals, Phathom Pharmaceuticals, AbbVie Pharmaceuticals; Consultant: Phathom Pharmaceuticals, Ardelyx Pharmaceuticals
- Charles Vega, MD, FAAFP
- Consultant: Boehringer Ingelheim, and Exact Sciences
- Shirah Vollmer, MD
- No relevant financial relationships disclosed
Other Disclosures
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.